Cell and Gene Therapy Business Outlook: Volume 1, Issue 7
22 Sep 2021
Categories:
Cell and Gene Therapy Business Outlook
Don't miss our new twice-monthly publication dedicated to cell and gene therapy. Cell and Gene Therapy Business Outlook offers the following:
- Market Sizing and Forecasting of CAGT Markets
- Executive News Summaries
- Deals Between CAGT Companies Tracked
- Financing
- Trends in the Industry
- Important Science That Will Shape Tomorrow’s Business
- Company Profiling and Quarterly Results Summaries
- Updates on Pipelines and Important Clinical Trials
- Cell and Gene Therapy Tools
- Cell and Gene Therapy CMOs
- And More
Table of Contents
- Untitled Chapter
-
Market Analysis
-
Focus on Neurological Diseases
- Overview of Neurological Diseases
- Market Outlook
- Products on the Market
- Products in Development
- Market Size and Growth
- Regional Market
- Top Company Briefs
- Conclusion
-
Focus on Neurological Diseases
-
Executive News Brief
- Recent developments in cell and gene therapy
-
Cell and Gene Therapy Market Financing
-
Over $800M in Financing in September So Far, Avantor Prices Stock Offering
- Mammoth, IASO See Financing
-
Over $800M in Financing in September So Far, Avantor Prices Stock Offering
-
Cell and Gene Therapy Market News and News Analysis
- Excision Granted FDA Approval for First Human Trial of a CRISPR-based HIV Treatment
- Precision BioSciences and iECURE Partner on Gene Editing Therapies
- ONK Therapeutics Granted Patent for CISH-knockout NK Cells
- Recent CGT Deal Activity